Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib in ALK inhibitor-treated ALK-positive NSCLC in China
NCT03909971Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2019
- Primary completion
- Aug 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Apr 2019; status: completed.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03909971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03909971.